Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Leases (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Current Leases for 13 consecutive years, with $7.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 14.93% year-over-year to $7.3 million, compared with a TTM value of $7.3 million through Sep 2025, up 14.93%, and an annual FY2025 reading of $7.3 million, up 14.93% over the prior year.
  • Current Leases was $7.3 million for Q3 2025 at Arrowhead Pharmaceuticals, up from $6.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $10.6 million in Q3 2023 and bottomed at $1.3 million in Q1 2021.
  • Average Current Leases over 5 years is $4.3 million, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Current Leases skyrocketed 280.51% in 2023, then crashed 39.96% in 2024.
  • Year by year, Current Leases stood at $2.8 million in 2021, then dropped by 1.77% to $2.8 million in 2022, then surged by 280.51% to $10.6 million in 2023, then plummeted by 37.9% to $6.6 million in 2024, then rose by 11.11% to $7.3 million in 2025.
  • Business Quant data shows Current Leases for ARWR at $7.3 million in Q3 2025, $6.6 million in Q4 2024, and $6.3 million in Q3 2024.